[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frontotemporal-dementia-ftd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frontotemporal-dementia-ftd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,92,110,136,173,204,245,272,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636721","a-wearable-sensor-platform-for-remote-monitoring-of-individuals-on-the-frontotemporal-dementia-spectrum-100636721",false,"NCT07569367","A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum","ReMoTe","Inclusion Criteria:\n\n* Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.\n* Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* Individuals who have a history of frequent falls defined as more than 5 falls per month.","ALL","40 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.",[24,25,26,27],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Corticobasal Degeneration","Corticobasal Syndrome (CBS)",[29,30,31],"digital health","wearable sensors","frontotemporal lobar degeneration","NOT_YET_RECRUITING","2026-05-05",{"date":35,"type":36},"2026-05-08","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2030-12-15",{"name":42,"class":43},"BioSensics","INDUSTRY",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":67,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100608375","speech-based-artificial-intelligence-for-detection-of-dementia-in-danish-patients-detectai-100608375","NCT07200739","Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)","Development of Deep Learning Models for Detection of Neurodegenerative Diseases Using Speech - a Danish Language-based Artificial Intelligence Study (DetectAI)","DetectAI","Inclusion Criteria:\n\nModel A (patient participants)\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n* A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment\n\nModel A (cognitively healthy controls)\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n\nModel B:\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n\nExclusion Criteria:\n\nModel A:\n\nPatients:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE score \\\u003C 16\n* Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression)\n* Patients unable to give consent\n* Patients with alcohol consumption \\>21 standard alcohol units per week\n* Any history of speech or language impairment predating the current condition\n\nCognitively healthy controls:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE \\\u003C 26 and ACE \\\u003C 90\n* Clinical, laboratory, or neuroradiological findings that could affect cognitive functions\n* Known diseases which are expected to impair cognitive functions\n* Any history of speech or language impairment predating the current condition\n* Patients with alcohol consumption \\>21 standard alcohol units per week.\n\nModel B:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE score \\\u003C 16\n* Patients unable to give consent\n* Patients with concomitant psychosis or severe psychiatric comorbidities other than depression\n* Any history of speech or language impairment predating the current condition",true,"50 Years",{"count":56,"type":20},440,"The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic. The main questions it aims to answer are:\n\nCan the AI model accurately distinguish between patients who need referral to a memory clinic (those with dementia or Mild Cognitive Impairment) and patients who don't (those with normal cognition or memory problems from other causes like depression)? Which speech patterns and cognitive test features are most useful for making this distinction?\n\nResearchers will compare speech recordings and cognitive test results from patients diagnosed with dementia or MCI to those from patients with normal cognition or non-neurodegenerative cognitive impairment to see if the AI model can reliably predict who needs specialist dementia care.\n\nParticipants will:\n\nComplete standard cognitive tests at the memory clinic Perform structured speech tasks while being audio-recorded Receive their usual clinical evaluation and diagnosis from memory clinic specialists\n\nThe results of this study will help develop a tool that can assist doctors in making faster, more accurate decisions about which patients need specialist dementia evaluation, potentially leading to earlier diagnosis and better patient outcomes.",[59,60,61,62,25,63,64,65,66],"Dementia (Diagnosis)","Alzheimer Dementia (AD)","Vascular Dementia (VaD)","Lewy Body Dementia (LBD)","Mild Cognitive Impairment (MCI)","Depression - Major Depressive Disorder","Stress","Cognitive Impairment",[68,69,70,71,72,73,74,75,76,62,25,63,77,78,79,80,66,81],"artificial intelligence","speech-based artificial intelligence","artificial intelligence in dementia diagnostics","artificial intelligence for dementia screening","artificial intelligence for dementia classification","speech based artificial intelligence","dementia","Vascular dementia (VaD)","Alzheimer dementia (AD)","Depression - Major Depressive disorder","Dementia (diagnosis)","machine learning","stress","deep learning","2026-04-28",{"date":33,"type":36},{"date":85,"type":20},"2026-06-01",{"date":87,"type":20},"2028-07",{"name":89,"class":90},"Zealand University Hospital","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100618613","digital-measurements-of-motor-and-voice-functions-in-ftd-100618613","NCT07333898","Digital Measurements of Motor and Voice Functions in FTD",{"count":98,"type":20},20,"The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes.\n\nResearchers at BioSensics and Johns Hopkins School of Medicine will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 20 patients with FTLD syndromes for 12 months with study visits every 3 months.",[24,25,101,102,26],"Corticobasal Syndrome","Corticobasal Syndrome(CBS)",[29,30,31],"2026-04-23",{"date":82,"type":36},{"date":38,"type":20},{"date":108,"type":20},"2028-12-31",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":91},"100631830","transcranial-alternating-current-stimulation-in-frontotemporal-dementia-100631830","NCT07505784","Transcranial Alternating Current Stimulation in Frontotemporal Dementia","Cross-over Study to Evaluate the Safety, Tolerability, and Clinical Efficacy of Transcranial Alternating Current Stimulation (tACS) in Patients With Frontotemporal Dementia","BetaTACSFTD","Inclusion Criteria:\n\n* Male or female subjects aged over 40 years at the time of signing the informed consent form;\n* Presence of a clinical diagnosis of Frontotemporal Dementia according to clinical criteria (Rascovsky et al., 2011; Gorno-Tempini et al., 2011).\n\nExclusion Criteria:\n\n* Age younger than that stated in the inclusion criterion;\n* Inability to understand;\n* Contraindications for tACS and TMS: cardiac pacemaker carriers and metal implants that are not compatible with electric or magnetic fields, history of epilepsy, current pregnancy (Safety Questionnaire)",{"count":119,"type":20},30,"INTERVENTIONAL",[122],"NA","The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation (tACS) in patients with Frontotemporal Dementia (FTD).\n\nIn addition to typical symptoms, FTD also present alterations in brain oscillations. In animal models of neurodegeneration, restoration of oscillations via neuronal \"entrainment\" phenomena has demonstrated a significant reduction in toxic protein accumulation, resulting in improved cognitive function.\n\ntACS is a neurophysiological noninvasive method of neuromodulation increasingly studied for its therapeutic potential. It has been shown to safely modulate the oscillatory frequencies underlying multiple cognitive functions, including verbal memory, perception, and working memory.\n\nIn light of this evidence, it is proposed to apply a single-session treatment of β-tACS stimulation in patients with FTD and to evaluate its clinical effects, oscillatory modifications by EEG, and changes in neurophysiological indices such as short intracortical inhibition (SICI) and intracortical facilitation (ICF), both compromised in the disease.\n\nThe study has a cross-over design (multicenter, randomized, placebo-controlled and double-blind), with FTD patients randomly assigned to one of the two arms: i) Group 1, who will receive a real tACS session first (1h); ii) Group 2, who will instead undergo a sham tACS session (1h). In the next phase (cross-over), one week after the first phase, the groups will reverse the treatment: Group 1 will receive tACS sham and Group 2 will receive real tACS.\n\nThe main objectives of the study are: \\[1\\] to evaluate the safety and tolerability of the single tACS treatment session; \\[2\\] to investigate the effects of the protocol on (short-term) cognitive performance in patients with FTD; \\[3\\] to verify intervention-induced changes in brain synchronization; \\[4\\] to evaluate changes in neurophysiological indices following treatment; and \\[5\\] evaluate any predictors of efficacy.",[125,25],"Transcranial Alternating Current Stimulation","RECRUITING","2026-03-26",{"date":129,"type":36},"2026-04-01",{"date":131,"type":36},"2026-02-03",{"date":133,"type":20},"2027-02",{"name":135,"class":90},"IRCCS Centro San Giovanni di Dio Fatebenefratelli",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":146,"conditions":147,"keywords":153,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100581941","disease-biosignatures-in-alsftd-spectrum-new-impactful-biological-perspectives-beyond-clinical-approaches-100581941","NCT06856850","Disease Biosignatures in ALS\u002FFTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches","SPECTRALS","Inclusion Criteria:\n\n* Clinical criteria for ALS (Brooks et al., 2000; de Carvalho M., 2008), FTD (GornoTempini et al., 2011; Rascovsky et al., 2011)\n\nExclusion Criteria:\n\n* na","18 Years",{"count":145,"type":20},230,"Diagnosis of ALS\u002FFTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more precise biological-based diagnosis. To achieve this aim, having access to proper specimens and analytical methods is crucial. Our team of experts in neurology, biology, chemistry, physics, and AI will explore ALS\u002FFTD from novel perspectives using transcriptomics, proteomics, genomics and other innovative approaches to analyzing easily accessible tissues. The seed amplification assay (SAA) will be also exploited to detect pathological TDP-43. This project aims to create disease fingerprints useful for patient stratification and monitoring of disease progression, and to evaluate the therapeutic efficacy in clinical trials, thus overcoming the limits of clinical interpretation. Discovering new biomarkers and cellular pathways will improve the diagnosis and treatment of these devastating diseases.",[148,149,150,151,152,25],"ALS (Amyotrophic Lateral Sclerosis)","FTD","Neuropathic","Psychiatric Disorders","Idiopathic Intracranial Hypertension",[154,155,156,157,158,159,160,161,162],"Amyotrophic lateral sclerosis","frontotemporal dementia","microbiota","miRNA","protein-NMR","TDP-43","endocytic disfunction","seed amplification assay","peripheral biomarker","2026-03-25",{"date":165,"type":36},"2026-03-30",{"date":167,"type":36},"2025-02-27",{"date":169,"type":20},"2026-08",{"name":171,"class":90},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",4,{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":53,"sex":16,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":120,"phases":183,"briefSummary":185,"conditions":186,"keywords":192,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":91},"100562542","phase-2-vortioxetine-for-the-treatment-of-mood-and-cognitive-symptoms-in-frontotemporal-dementia-100562542","NCT06604520","Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia","Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia","FTD Patients\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)\n4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation\n5. A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one\n6. Patients must be medically stable\n7. Vortioxetine treatment is clinically indicated\n8. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No history of drug or alcohol dependence within six months prior to study entry\n2. Negative toxicology screening for drugs of abuse\n3. Subject must not be pregnant or nursing\n4. No contraindications to Vortioxetine treatment\n5. No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)\n\nHealthy Controls\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Subjects must be medically stable\n4. Free of psychotropic medications\n5. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No current or past history of neurological or psychiatric illness or substance abuse\n2. Subject must not be pregnant or nursing\n3. Negative toxicology screening for drugs of abuse\n4. No contraindications for MR scanning (e.g. metal implanted in the body)","45 Years",{"count":182,"type":20},50,[184],"PHASE2","The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:\n\n1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?\n2. Do mood symptoms and cognition improve following treatment with vortioxetine?\n\nResearchers will also determine whether there are changes in the brain associated with vortioxetine treatment.\n\nParticipants will:\n\n* Undergo a screening visit that involves clinical assessments and laboratory tests\n* Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine\n* Undergo memory and problem-solving tests before starting treatment with vortioxetine\n* Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist\n* Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine",[187,188,189,25,190,191],"Fronto-temporal Dementia","Fronto-temporal Lobar Dementia","Frontotemporal Degeneration","Frontotemporal Dementia, Behavioral Variant","Frontotemporal Dementia",[149,191,193,194],"Neuropsychiatric Symptoms","Antidepressant","2026-03-05",{"date":197,"type":36},"2026-03-09",{"date":199,"type":36},"2025-03-20",{"date":201,"type":20},"2029-09-01",{"name":203,"class":90},"Johns Hopkins University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":215,"conditions":216,"keywords":225,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure","90 Years",{"count":214,"type":20},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[217,63,218,219,220,221,25,222,223,224],"Dementia","Subjective Cognitive Impairment","Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Alzheimer Disease (AD)","Cognitively Unimpaired","Subjective Cognitive Decline (SCD)",[226,217,227,228,229,230,231,232,233,234],"Observational","Alzheimer's Disease","Parkinson's Disease","Biosample","Genetics","Neuropsychological","MRI","Microbiome","Plasma","2026-01-15",{"date":237,"type":36},"2026-01-20",{"date":239,"type":36},"2016-06",{"date":241,"type":20},"2029-12",{"name":243,"class":90},"McGill University",19,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":120,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":268,"leadSponsor":270,"locationsCount":91},"100591324","deep-cervical-lymphaticovenous-anastomosis-surgery-for-moderate-to-advanced-dementia-patients-100591324","NCT06978946","Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients","Clinical Efficacy and Safety of Deep Cervical Lymphaticovenous Anastomosis (DLVA) in Moderate-to-Severe Neurodegenerative Dementia","Inclusion Criteria:\n\n1. Age between 50-80 years\n2. AD participants meet the diagnostic criteria for Alzheimer's disease established by the National Institute on Aging and the Alzheimer's Association (NIA-AA); FTD participants meet the diagnostic criteria defined by the International Consortium on FTD; DLB participants meet the 2017 diagnostic criteria of the DLB Consortium; PDD participants meet the 2007 diagnostic criteria of the Movement Disorder Society or the 2011 Chinese diagnostic guidelines for PDD;\n3. Mini-Mental State Examination (MMSE)\\\u003Cthan 21, Montreal Cognitive Assessment (MoCA) score\\\u003C17, and Clinical Dementia Rating (CDR) score ≥2;\n4. Diagnosed by clinicians as having moderate to severe disease;\n5. On stable medication regimen for ≥1 month\n6. Signed informed consent and demonstrated good compliance\n\nExclusion Criteria:\n\n1. Dementia caused by other conditions, including: vascular dementia; central nervous system infections due to HIV, syphilis, etc.; Creutzfeldt-Jakob disease; Huntington's disease; traumatic brain injury-related dementia; dementia due to toxic or alcohol-related factors; major systemic diseases such as hepatic or pulmonary encephalopathy; subdural hematoma; endocrine disorders such as thyroid or parathyroid disease; vitamin deficiency; or any other cause of dementia.\n2. Presence of severe or unstable medical conditions, including but not limited to cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, neurological (excluding cognitive impairment), psychiatric, immunological, or hematological disorders, or any other condition deemed by the investigator to potentially interfere with study results; or life expectancy \\\u003C 24 months.\n3. Current diagnosis of any primary psychiatric disorder other than cognitive impairment. If, in the investigator's opinion, the psychiatric condition or symptoms may interfere with cognitive assessment or the subject's ability to complete the study, exclusion is required. Subjects with a history of schizophrenia or other chronic psychotic disorders should also be excluded.\n4. Contraindications to deep cervical LVA surgery, including left vagus nerve injury, severe infection at the surgical site, significant dysfunction of the heart, lungs, liver, kidneys, or other organ systems, a history of head and neck radiation therapy or surgery, preoperative anesthetic evaluation of ASA grade III or above, or inability to tolerate prolonged surgery.","80 Years",{"count":254,"type":20},85,[122],"This clinical trial aims to evaluate the clinical efficacy and safety of Deep Cervical Lymphaticovenous Anastomosis (DLVA) in patients aged 50-80 with moderate to severe neurodegenerative dementia. Participants will undergo surgical treatment, followed by cognitive assessments, PET\u002FMRI scans, lymph fluid\u002Fcerebrospinal fluid collection, and blood tests. Additionally, the study will perform an in-depth analysis of DLVA's therapeutic mechanisms using multimodal imaging and molecular biology experiments.",[258,62,25,217,259],"Alzheimer Disease","Parkinsons Disease With Dementia (PDD)",[261,62,25,262,263],"Alzheimer Diseas","Lymphaticovenous Anastomosis","Parkinsons Disease","2025-05-27",{"date":266,"type":36},"2025-05-28",{"date":266,"type":20},{"date":269,"type":20},"2027-02-28",{"name":271,"class":90},"RenJi Hospital",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":120,"phases":282,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":91},"100584620","early-phase-1-18faci-19626-pet-in-tdp-43-proteinopathies-100584620","NCT06891716","[18F]ACI-19626 PET in TDP-43 Proteinopathies","Phase 1 Study to Evaluate [18F]ACI-19626 as a Potential PET Radioligand for Imaging TDP-43 Inclusions in the Brain of Patients With Suspected TDP-43 Proteinopathies Compared With Healthy Controls","Inclusion Criteria for all Participants:\n\n* Subject is able to provide written informed consent (IC), which must be obtained before any assessment is performed.\n* Female subjects must not be of childbearing potential, or if they are of childbearing potential to agree to use reliable contraception method(s) and not donate eggs for 30 days after the PET scan. Subjects without documentation of non-childbearing potential will perform serum pregnancy testing at screening and urine pregnancy test before the PET scan. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the PI (e.g., Müllerian agenesis). Women of childbearing potential must commit to remain abstinent (refrain from heterosexual intercourse) or use a reliable form of birth control (e.g. a barrier, hormonal contraception method or intrauterine device), during the study and until 30 days after the last PET scan. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. Women of childbearing potential must commit to not donate ovum during the study and until 30 days after the last PET scan.\n* Male subjects with their partners of childbearing potential must commit to the use of a barrier method of contraception during the study and until 90 days after the last PET scan.\n* Male subjects must commit to not donate sperm during the study and until 90 days after the last PET scan.\n* Willing and able to cooperate with study procedures.\n* Ability to tolerate lying in the scanner for up to 90 minutes without excessive movements sufficient to cause significant motion artifact on the PET scans, or if necessary up to 120 minutes with a break.\n* For subjects receiving arterial cannulation, adequate circulation to the hand for safe placement of arterial line and coagulation (International Normalized Ratio \\[INR\\], Prothrombin Time \\[PT\\] and Partial Thromboplastin Time \\[PTT\\]).\n\nAdditional Inclusion Criteria for Healthy Controls:\n\n* Males and females aged 40-70 years.\n* Healthy with no clinically relevant finding on physical and neurological examination at Screening and upon reporting to the clinic for the \\[18F\\]ACI-19626 Imaging Visit.\n* No family history of TDP-43 proteinopathies, including FTD, ALS, or other early-onset neurological disease associated with dementia and\u002For movement disorders.\n* No personal history of clinically significant neurological and\u002For psychiatric disorders.\n* No evidence of neurodegeneration or other neurological pathology on magnetic resonance imaging (MRI) performed either as part of Screening or on previously acquired MRI scan (within 6 months prior to signing consent).\n* Montreal Cognitive Assessment (MoCA) score ≥ 26.\n* No cognitive or behavioural impairment as judged by the PI.\n\nAdditional Inclusion Criteria for Participants with TDP-43 proteinopathies:\n\n* Males and females aged ≥ 40 years.\n* Subjects diagnosed with any of the following: GRN, C9Orf72 or other mutation carriers with the CDR® plus NACC FTLD-GS of ≥ 0.5; sporadic probable behavioral FTD per International consensus criteria or primary progressive aphasia, with or without clinical or electrophysiological indications of MND; ALS meeting the El Escorial criteria of probable or possible ALS; Other neurodegenerative diseases, e.g. AD or suspected LATE pathology\n* Confirmed genetic status for the subjects with genetic FTD, FTD-MND or ALS (e.g. GRN, C9orf72 or other mutations)\n* For sporadic FTD \u002F FTD-MND subjects: brain MRI consistent with a diagnosis of FTD, with no evidence of focal disease to account for the subject's neurological, cognitive or behavioral symptoms.\n\nExclusion Criteria for All Participants:\n\n* Current or prior history of any alcohol or drug abuse in the past 2 years.\n* Laboratory tests with clinically significant abnormalities and\u002For clinically significant unstable medical condition.\n* Known history of hypersensitivity, including hypersensitivity to the active substances used for \\[18F\\]ACI-19626 or derivatives, or to any of the associated excipients.\n* Prior participation in other research protocols or clinical care during the past year that would result in radiation exposure to an effective radiation dose exceeding the acceptable annual limit (including the procedures in this clinical protocol).\n* Pregnant or lactating.\n* Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease.\n* Unsuitable veins for repeated venipuncture.\n* Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.\n* Treatment with any antihemostasis medication (e.g., warfarin, heparin, thrombin inhibitors, Factor Xa inhibitors, streptokinase, urokinase, tissue plasminogen activators) within 2 weeks of the planned arterial cannula placement (if performed) of either the baseline or retest imaging.\n* Anaemia (for subjects undergoing arterial cannulation) considered clinically significant by the PI\n* Coagulopathies\n* Loss or donation of blood over 500 mL within four months prior to study visits for subjects undergoing arterial cannulation\n* Subject has received an investigational drug within the last 30 days or 5 half-lives prior to the screening assessments, whichever is longer unless there is documented evidence that the subject was treated with placebo only.\n\nAdditional Exclusion Criteria for Participants with TDP-43 proteinopathies:\n\n* Prior participation in DMT clinical trials which could interfere with the TDP-43 protein itself or its metabolism, including but not limited to gene therapy, unless there is documented evidence that the subject was treated with placebo only.\n* MRI scan showing structural evidence of alternative pathology not consistent with TDP-43 proteinopathies which could cause the subject's symptoms.\n* Mutations with known absence of TDP-43 pathology, e.g. SOD1 or FUS.","70 Years",{"count":281,"type":20},45,[283],"EARLY_PHASE1","The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 \\[involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic lateral sclerosis (ALS)\\] using a new positron emission tomography (PET) tracer called \\[18F\\]ACI-19626. Both healthy people and people with (suspected) TDP-43 accumulation will participate to this trial.\n\nThe main questions it aims to answer are:\n\n* whether \\[18F\\]ACI-19626 is safe and well tolerated when injected into participants\n* whether \\[18F\\]ACI-19626 reliably detects abnormal TDP-43 in the brain using PET technique.\n* whether there are differences in the amount of this protein between people with diseases related to TDP-43 accumulation in the brain and people without these diseases.\n\nParticipants will:\n\n* Visit the clinic to consent to their participation and to ensure they are eligible (physical and neurological examinations, questionnaires, blood and urine tests, ECG and MRI in some cases).\n* Visit the clinic to receive the tracer \\[18F\\]ACI-19626 intravenously and be scanned in a PET scanner, during which blood will be collected.\n* Receive a phone call from the clinic 2 to 4 days after the PET scan to report any symptoms and side-effects that they may be having.\n\nSome of the participants may be asked to come again to the clinic for a second PET scan, allowing the researchers to determine if the measurements with the first PET scan are stable and reproducible.",[25,286,287,288,289],"Amyotrophic Lateral Sclerosis (ALS)","TDP-43 Proteinopathies","Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)","Alzheimer's Disease (AD)","2025-03-18",{"date":292,"type":36},"2025-03-24",{"date":294,"type":36},"2025-01-21",{"date":296,"type":20},"2026-11",{"name":298,"class":43},"AC Immune SA",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":53,"sex":16,"minAge":305,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":91},"100577860","discovery-and-validation-of-protein-structural-complexes-in-circulating-biofluids-as-novel-biomarkers-for-early-diagnosis-prognosis-and-therapeutic-management-of-patients-affected-by-neurodegenerative-disorders-100577860","NCT06803784","Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders","* Inclusion Criteria:\n* Inclusion criteria for PD patients.\n\nFor the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli. Affected subjects will be selected according to the criteria proposed by Gelb et al in 1999. This is a very pragmatic scheme based on the presence of four cardinal signs, the response to a test administration of Levodopa and the absence of atypical signs:\n\nA) Presence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset) one of which must be tremor or bradykinesia; B) Absence of atypical symptoms such as: i) early postural instability, freezing phenomena, cognitive deterioration, hallucinations, pathological involuntary movements, vertical gaze paralysis; ii) proven causes of secondary parkinsonism (focal lesions, drugs, toxic substances); C) Documented response to the use of L-dopa or dapamine agonists (or lack of an adequate therapeutic attempt with L-dopa or dopamine agonists).\n\n* Inclusion criteria forAD patients. Patients will be selected at the Center for Cognitive Disorders and Dementias (CDCD) SCDU Neurology, AOU Maggiore della Carità, Novara. Patients with AD will be included after diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011) and supported by positive biomarkers for amyloidopathy (PET with amyloid tracer or amyloid cerebrospinal fluid dosage).\n* Inclusion criteria for FTD\u002FALS patients. For UPO, patients will be selected at the tertiary center Amyotrophic Lateral Sclerosis - SCDU Neurology, AOU Maggiore della Carità, Novara. Patients with amyotrophic lateral sclerosis will be included following a diagnosis according to the El Escorial criteria - revised (2015): in this regard, only patients with a definite or probable diagnosis supported by laboratory will be included. For patients with FTD, they will be selected at both centers mentioned above with a diagnosis according to the Rascovsky criteria (2011). In this group, the diagnosis will be supported by negative biomarkers for amyloidopathy (PET with amyloid tracer or amyloid cerebrospinal fluid dosage). For patients with concomitant ALS and FTD, the El Escorial criteria (2015) associated with the Strong criteria (2017) will be used.\n\nExclusion Criteria:\n\n* PD PATIENTS\n\n  * pre-existing psychiatric pathologies;\n  * neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, neuromuscular diseases, epilepsy;\n  * diagnosis of dementia;\n* AD\u002FFTD\u002FALS PATIENTS\n\n  * pre-existing psychiatric pathologies;\n  * previous diagnosis of other neurodegenerative neurological diseases;\n  * patients unable to sign informed consent.\n* CONTROLS\n\n  * pre-existing psychiatric pathologies;\n  * neurodegenerative neurological diseases such as Parkinson's, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's, neuromuscular diseases, epilepsy;\n  * diagnosis of dementia;\n  * depression;\n  * prolonged intake of anxiolytic, antidepressant, antipsychotic, sleep-inducing, cognitive stimulant drugs.","20 Years",{"count":307,"type":20},110,"Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation of misfolded proteins, which are believed to play a key role in synaptic dysfunction and neuronal death. Protein structural complexes in biofluids have been proposed to mirror pathological conditions suggesting their use as biomarkers for NDDs characterized by protein aggregation. In this framework, we plan to: i) collect a large cohort of NDD and prodromal patients and healthy subjects using standardized clinical and genetics procedures; ii) apply a novel method based on genomics, proteomics and bioinformatic analysis to map protein complexes in biofluids; iii) identify novel circulating biomarkers and correlate them to genetic profiling and disease endophenotypes, and; iv) validate the biological properties in human brain tissue and dopaminergic cultures.",[310,286,25,311],"Parkinson Disease","Alzheimer's Disease (AD)",[313,314],"protein structural complexes in Neurodegenerative diseases","circulating biomarkers for neurodegenerative diseases","2025-03-17",{"date":290,"type":36},{"date":318,"type":36},"2025-02-04",{"date":320,"type":20},"2026-12",{"name":322,"class":90},"Neuromed IRCCS"]